Tag: mortality risk

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled...

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled...

Canada Life Reinsurance strengthens focus on structured reinsurance; ceases new business for U.S. traditional mortality risk reinsurance

BLUE BELL, Pa., June 25, 2025 /PRNewswire/ - Today, Canada Life Reinsurance, a wholly owned subsidiary of Great-West Lifeco Inc. (TSX: GWO) ("Lifeco") announced...

EAN Congress: Frequent nightmares triple risk of early death and accelerate ageing, major study finds

HELSINKI, June 23, 2025 /PRNewswire/ -- New research presented today at the European Academy of Neurology (EAN) Congress 2025 reveals that frequent nightmares are...

EAN Congress: Frequent nightmares triple risk of early death and accelerate ageing, major study finds

HELSINKI, June 23, 2025 /PRNewswire/ -- New research presented today at the European Academy of Neurology (EAN) Congress 2025 reveals that frequent nightmares are...

EAN Congress: Frequent nightmares triple risk of early death and accelerate ageing, major study finds

HELSINKI, June 23, 2025 /CNW/ -- New research presented today at the European Academy of Neurology (EAN) Congress 2025 reveals that frequent nightmares are...

EAN Congress: Frequent nightmares triple risk of early death and accelerate ageing, major study finds

HELSINKI, June 23, 2025 /PRNewswire/ -- New research presented today at the European Academy of Neurology (EAN) Congress 2025 reveals that frequent nightmares are...

Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025

HONG KONG, June 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") presented the subgroup analysis data from the Phase III COMPASSION-16...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsMortality risk

New Product Safety Recalls

Adecoagro And Tether To Power Bitcoin Mining With Renewable Energy In Brazil

$5 Bn Pet Supplements Market Trends, Analysis, and Forecasts 2025-2034 | AI-Driven Personalized Nutrition and CBD-Infused Supplements Transforming Pet Health

Tag: mortality risk

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

Canada Life Reinsurance strengthens focus on structured reinsurance; ceases new business for U.S. traditional mortality risk reinsurance

EAN Congress: Frequent nightmares triple risk of early death and accelerate ageing, major study finds

EAN Congress: Frequent nightmares triple risk of early death and accelerate ageing, major study finds

EAN Congress: Frequent nightmares triple risk of early death and accelerate ageing, major study finds

EAN Congress: Frequent nightmares triple risk of early death and accelerate ageing, major study finds

Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us